Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions

Glasmacinal was well tolerated in single doses up to 750 mg and repeat doses up to 375 mg. Glasmacinal may be a victim of selected drugs that impact CYP3A4 and/or P-gp but is unlikely to be a perpetrator of clinically relevant DDIs.